TriSalus Life Sciences, Inc. (TLSIW)
2025-06-30 | ||||
|---|---|---|---|---|
| Revenue | 11,213 | |||
| Cost of goods sold | 1,802 | |||
| Gross profit | 9,411 | |||
| General and administrative | 5,657 | |||
| Research and development | 3,923 | |||
| Sales and marketing | 7,163 | |||
| Loss from operations | -7,332 | |||
| Interest income | 134 | |||
| Interest expense | 1,423 | |||
| Change in fair value of contingent earnout liability | -700 | |||
| Change in fair value of sepa, warrant, and revenue base redemption liabilities | -330 | |||
| Other expense, net | -40 | |||
| Loss before income taxes | -8,291 | |||
| Income tax benefit (expense) | -3 | |||
| Net loss available to common stockholders | -8,288 | |||
| Undeclared dividends on series a preferred stock | 714 | |||
| Net loss attributable to common stockholders | -9,002 | |||
| Net loss per common share, basic (in dollars per share) | -0.27 | |||
| Net loss per common share, diluted (in dollars per share) | -0.27 | |||
| Weighted average common shares outstanding, basic (in shares) | 32,899,297 | |||
| Weighted average common shares outstanding, diluted (in shares) | 32,899,297 | |||